GSK tar­gets a new in­di­ca­tion for Nu­cala, flags PhI­II suc­cess for a rare dis­ease

Glax­o­SmithK­line may soon have a new mar­ket for its asth­ma drug Nu­cala (mepolizum­ab). The phar­ma gi­ant says that their Phase III study of the drug for a rare dis­ease char­ac­ter­ized by in­flam­ma­tion of small blood ves­sel walls came through with fly­ing col­ors.

In­ves­ti­ga­tors at GSK, work­ing with a team at the NIH, say the drug hit both co-pri­ma­ry end­points as well as all sec­ondary end­points in their late-stage study of the drug in pa­tients suf­fer­ing from Eosinophilic Gran­u­lo­mato­sis with Polyangi­itis, or EG­PA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.